Accretion Nutraveda SME IPO
Accretion Nutraveda IPO — date, price band, GMP & allotment 2026
Accretion Nutraveda’s IPO was a fresh issue of around ₹24.77 crore with a price band of ₹122‑₹129 per share, and it was open for subscription from 28 Jan to 30 Jan 2026 on the BSE SME platform. The company is a healthcare‑focused CDMO that manufactures Ayurvedic and nutraceutical products like tablets, capsules, liquids, powders and oils, blending traditional Ayurvedic formulations with modern science. The funds are mainly for new machinery, automation, working capital and general corporate needs.
Stock price
Accretion Nutraveda is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 September.
- Open 28 Jan 2026
- Close 30 Jan 2026
- Allotment 02 Feb 2026
- Refund/credit 03 Feb 2026
- Listing 04 Feb 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 28 to 30 Jan, 2026 |
|---|---|
| Price Band | ₹122 – ₹129 |
| Face Value | ₹10 |
| Lot Size | 1000 Shares |
| Issue Size | ₹24.77 Cr. Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE SME |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 2,58,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 1000 shares at the ₹129 cut-off. The SME retail application is a fixed 2 lots; HNI starts at 3.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 2 | 2,000 | ₹2,58,000 |
| Retail (max) | 2 | 2,000 | ₹2,58,000 |
| HNI (min) | 3 | 3,000 | ₹3,87,000 |
Three years of numbers
All figures in ₹ crore, as reported in the Accretion Nutraveda offer document.
| Metric | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 16.35 | 10.86 | 4.64 | 4.06 |
| Total Income | 14.07 | 16.06 | 5.20 | 3.07 |
| Profit After Tax | 2.33 | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
| NET Worth | 8.26 | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 2.95 | 4.86 | 0.72 | -0.10 |
| Total Borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
See how this IPO compares — view listing performance of all SME IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Accretion Nutraveda RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Accretion Nutraveda IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹6.44 |
| P/E Ratio (x) | 20.02 |
| Market Cap at Offer Price (₹ Cr) | ₹46.67 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹129 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹27.46 Cr of the issue is earmarked to named objects.
About the company
The company operates as a Contract Development and Manufacturing Organization (CDMO), serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.
Interested in this IPO? Check the live subscription status or browse all upcoming SME IPOs.
+91- 9904366177
The bankers & the filings
Who is running the book, and the documents this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Sobhagya Capital Options Pvt.Ltd.
4 issues handledBest listing: Safety Controls & Devices (+3.8%). Weakest: UHM Vacation (-20.0%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Accretion Nutraveda?
The current Grey Market Premium is ₹65, or 50% over the issue price.
What is the Accretion Nutraveda IPO price band?
₹122 to ₹129, on a face value of ₹10.
When is the allotment?
The basis of allotment is 2 February 2026, with listing on 4 February 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every SME and Mainboard issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
